Table 3.
The comparative risk of RVO between sinusitis and non-sinusitis cohorts.
| Event: Retinal vein occlusion | Event: Central retinal vein occlusion | Event: Branch retinal vein occlusion | ||||
|---|---|---|---|---|---|---|
| Non-sinusitis cohort | Sinusitis cohort | Non-sinusitis cohort | Sinusitis cohort | Non-sinusitis cohort | Sinusitis cohort | |
| Follow-up person-month | 39,821,930 | 20,197,467 | 39,858,965 | 20,221,827 | 39,848,598 | 20,216,180 |
| Event | 701 | 481 | 141 | 114 | 272 | 192 |
| Incidence density (95% CI) |
1.76 (1.63–1.90) |
2.38 (2.17–2.60) |
0.35 (0.30–0.42) |
0.56 (0.47–0.68) |
0.68 (0.60–0.77) |
0.95 (0.82–1.09) |
| Crude HR | Reference | 1.35 (1.20–1.52) | Reference | 1.60 (1.25–2.04) | Reference | 1.39 (1.16–1.68) |
| aHR1 | Reference | 1.33 (1.18–1.49) | Reference | 1.56 (1.22-2.00) | Reference | 1.37 (1.14–1.65) |
| aHR2 | Reference | 1.27 (1.13–1.43) | Reference | 1.50 (1.16–1.92) | Reference | 1.33 (1.10–1.60) |
| aHR3 | Reference | 1.28 (1.13–1.44) | Reference | 1.51 (1.16–1.96) | Reference | 1.36 (1.12–1.65) |
| IPTW HR | Reference | 1.32 (1.22–1.43) | Reference | 1.58 (1.33–1.88) | Reference | 1.41 (1.25–1.60) |
Incidence density, defined as event cases per 100,000 person-months, along with the 95% confidence interval (CI), was calculated using the normal approximation to the Poisson distribution.
aHR1, adjusted for demographics.
aHR2, adjusted for demographics and co-morbidities.
aHR3, adjusted for demographics, co-morbidities, and co-medications.
IPTW HR, inverse probability of treatment weighted hazard ratio.